

Fadi Fakhouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/186839/publications.pdf>

Version: 2024-02-01

63
papers

6,402
citations

117625

34
h-index

128289

60
g-index

64
all docs

64
docs citations

64
times ranked

4438
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 554-562.	4.5	567
2	C3 glomerulopathy: consensus report. <i>Kidney International</i> , 2013, 84, 1079-1089.	5.2	505
3	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. <i>Nature Genetics</i> , 2013, 45, 531-536.	21.4	419
4	Haemolytic uraemic syndrome. <i>Lancet, The</i> , 2017, 390, 681-696.	13.7	397
5	Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 859-867.	6.1	383
6	C3 glomerulopathy: a new classification. <i>Nature Reviews Nephrology</i> , 2010, 6, 494-499.	9.6	314
7	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2006, 44, 193-199.	3.2	259
8	Collapsing glomerulopathy in a COVID-19 patient. <i>Kidney International</i> , 2020, 98, 228-231.	5.2	240
9	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 84-93.	1.9	230
10	Steroid-sensitive nephrotic syndrome: From childhood to adulthood. <i>American Journal of Kidney Diseases</i> , 2003, 41, 550-557.	1.9	164
11	ANCA-negative pauci-immune renal vasculitis: histology and outcome. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1392-1399.	0.7	150
12	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 50-59.	4.5	148
13	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1237-1247.	4.5	146
14	Liver Involvement in Autosomal-Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 1767-1775.	6.1	127
15	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. <i>Kidney International</i> , 2018, 94, 408-418.	5.2	117
16	Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Blood</i> , 2008, 112, 4542-4545.	1.4	112
17	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. <i>Kidney International</i> , 2010, 78, 279-286.	5.2	94
18	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2018, 72, 84-92.	1.9	94

#	ARTICLE	IF	CITATIONS
19	The expanding spectrum of renal diseases associated with antiphospholipid syndrome. <i>American Journal of Kidney Diseases</i> , 2003, 41, 1205-1211.	1.9	93
20	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	5.2	93
21	Etiology and Outcomes of Thrombotic Microangiopathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 557-566.	4.5	89
22	Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2015, 65, 484-489.	1.9	87
23	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. <i>Blood</i> , 2021, 137, 2438-2449.	1.4	87
24	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020, 136, 2103-2117.	1.4	82
25	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	6.1	81
26	Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. <i>American Journal of Kidney Diseases</i> , 2014, 63, 40-48.	1.9	74
27	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and a common genetic risk factors. <i>Kidney International</i> , 2019, 95, 1443-1452.	5.2	74
28	Loss of DGK μ induces endothelial cell activation and death independently of complement activation. <i>Blood</i> , 2015, 125, 1038-1046.	1.4	69
29	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. <i>Nature Reviews Nephrology</i> , 2021, 17, 543-553.	9.6	64
30	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. <i>Kidney International Reports</i> , 2019, 4, 434-446.	0.8	59
31	Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 679-687.	2.0	53
32	Atypical HUS relapse triggered by COVID-19. <i>Kidney International</i> , 2021, 99, 267-268.	5.2	46
33	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. <i>Haematologica</i> , 2019, 104, 2501-2511.	3.5	40
34	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	5.8	32
35	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. <i>Kidney International</i> , 2020, 98, 1135-1148.	5.2	28
36	Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 70-76.	3.4	27

#	ARTICLE	IF	CITATIONS
37	Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". <i>Kidney International</i> , 2021, 100, 458-459.	5.2	24
38	Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 641-650.	5.6	23
39	Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. <i>Journal of Nephrology</i> , 2021, 34, 1581-1590.	2.0	23
40	COVID-19 as a potential trigger of complement-mediated atypical HUS.. <i>Blood</i> , 2021, 138, 1777-1782.	1.4	18
41	The Rational Use of Complement Inhibitors in Kidney Diseases. <i>Kidney International Reports</i> , 2022, 7, 1165-1178.	0.8	16
42	Crystals from fat. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1348-1350.	0.7	15
43	Mesangial IgG Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 379-387.	6.1	15
44	Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1225-1231.	0.7	14
45	Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. <i>Pediatric Nephrology</i> , 2016, 31, 41-51.	1.7	13
46	Antenatal corticosteroid therapy and COVID-19: Pathophysiological considerations. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 952-952.	2.8	11
47	ANCA-Negative Pauci-immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. <i>American Journal of Kidney Diseases</i> , 2022, 79, 56-68.e1.	1.9	11
48	Eculizumab for atypical haemolytic uraemic syndrome: what next?. <i>Nature Reviews Nephrology</i> , 2013, 9, 495-496.	9.6	10
49	Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. <i>Antibodies</i> , 2017, 6, 19.	2.5	10
50	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. <i>Kidney International Reports</i> , 2021, 6, 746-754.	0.8	8
51	What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study. <i>BMC Nephrology</i> , 2022, 23, 39.	1.8	8
52	C3 glomerulonephritis in a patient treated with anti-PD-1 antibody. <i>European Journal of Cancer</i> , 2020, 125, 46-48.	2.8	6
53	Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1355-1364.	4.5	6
54	Shiga toxin-producing <i>Escherichia coli</i> -associated hemolytic uremic syndrome in solid organ transplant recipients. <i>Kidney International</i> , 2019, 96, 1423-1424.	5.2	5

#	ARTICLE	IF	CITATIONS
55	Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases. CKJ: Clinical Kidney Journal, 2009, 2, 143-146.	2.9	3
56	Monitoring Complement Activation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1682-1683.	4.5	3
57	Malignant hypertension and thrombotic microangiopathy: complement as a usual suspect. Nephrology Dialysis Transplantation, 2021, 36, 1157-1159.	0.7	3
58	The authors reply. Kidney International, 2020, 98, 232.	5.2	3
59	The man with "milk-shake" urine. Lancet, The, 2004, 364, 1638.	13.7	2
60	Eosinophilia Due to Central Venous Catheter in Hemodialysis Patients. Kidney International Reports, 2021, 6, 1189-1191.	0.8	1
61	The authors reply. Kidney International, 2019, 96, 517-518.	5.2	0
62	High levels of interleukine-6 in ascites prevent ascites reinfusion during hemodialysis. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101734.	1.5	0
63	Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients. Kidney and Dialysis, 2022, 2, 6-15.	1.0	0